Werewolf Therapeutics Inc
For the period ended Dec 31, 2023. Filed Mar 7, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 7, 2024
HOWL$1.010.0%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Operations
1z
(amounts in thousands, except share and per share amounts)
| Year Ended December 31, | ||
|---|---|---|
| 2023 | 2022 | |
| Revenue: | ||
| Collaboration revenue | $19,943 | $16,401 |
| Operating expenses: | ||
| Research and development | 41,776 | 53,761 |
| General and administrative | 18,670 | 18,696 |
| Total operating expenses | 60,446 | 72,457 |
| Operating loss | (40,503) | (56,056) |
| Other income: | ||
| Interest income | 7,416 | 1,908 |
| Interest expense | (3,139) | — |
| Other (expense) income, net | (1,142) | 338 |
| Total other income | 3,135 | 2,246 |
| Net loss | $(37,368) | $(53,810) |
| Net loss per share attributable to common stockholders, basic and diluted | $(1.05) | $(1.86) |
| Weighted-average common shares outstanding, basic and diluted | 35,646,572 | 28,863,935 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.